Acurx Pharmaceuticals CEO on Microbiome-Sparing Antibiotics and Phase 3 Trials

Novel Antibiotic Class Discovery

• 💡 Acurx Pharmaceuticals has published new data in Nature magazine validating a novel class of Pol III inhibitor antibiotics.
• 🔬 This innovation stems from a public-private partnership with Leiden University Medical Center in the Netherlands, sponsored by the Dutch government.
• 🎯 The core mechanism involves blocking the Pol III enzyme, effectively starving and killing bacterial cells.

Microbiome-Sparing Mechanism

• ✅ A key finding is that these antibiotics are microbiome-sparing, meaning they kill harmful bacteria while preserving healthy gut flora.
• 🚀 This is a significant leap forward, as typical antibiotics often cause microbiome destruction, leading to reinfection and other health issues.
• 🎯 The class effect applies to antibiotics targeting C. difficile, MRSA, anthrax, and VRE.

Clinical Development and C. difficile

• 🏥 The lead antibiotic, pulsad, is entering Phase 3 clinical trials for C. difficile infections.
• ⚠️ C. difficile causes 29,000 deaths and 500,000 cases annually in the U.S., with high recurrence rates even with standard treatments.
• 📈 Prior trials showed 96% cure rates for C. difficile with zero reinfections on their drug.
• 🔬 An ongoing lab study at the University of Houston is comparing pulsad to standard treatments against resistant C. diff bacteria.

Future Pipeline and Partnerships

• 🤝 Acurx is pursuing government sponsorship for its Phase 3 C. difficile program and has a potential partnership for a second antibiotic candidate targeting MRSA, anthrax, and VRE.
• 📅 Upcoming news includes data from the University of Houston study, a new contract for further research with Leiden University, and the start of a 10-20 patient trial for recurrent C. diff.
• 📈 The company anticipates significant news and potential M&A activity in the near future.